Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ABBOTT LABORATORIES Regulatory Filings 2021

Jun 28, 2021

29777_rns_2021-06-28_71c6306f-4053-407f-8163-aaee30681d06.zip

Regulatory Filings

Open in viewer

Opens in your device viewer

11-K 1 tm2120640d1_11k.htm FORM 11-K

Field: Rule-Page

Field: /Rule-Page

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549

Field: Rule-Page

Field: /Rule-Page

FORM 11-K

FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

(Mark One)

x
For the fiscal year ended December 31, 2020

OR

¨ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____ to _______

Commission File Number 1-2189

A. Full title of the plan and the address of the plan, if different from that of the issuer named below:

ABBOTT LABORATORIES STOCK RETIREMENT PROGRAM

B. Name of issuer of the securities held pursuant to the plan and the address of its principal executive office:

ABBOTT LABORATORIES

100 Abbott Park Road

Abbott Park, Illinois 60064-6049

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

FINANCIAL STATEMENTS AND

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

ABBOTT LABORATORIES STOCK RETIREMENT PLAN

DECEMBER 31, 2020 AND 2019

Field: Page; Sequence: 2

Field: /Page

C O N T E N T S

Page

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 3
FINANCIAL STATEMENTS
STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS 5
STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS 6
NOTES TO FINANCIAL STATEMENTS 7
SUPPLEMENTAL SCHEDULE
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) 18

Field: Page; Sequence: 3

Field: /Page

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Plan Administrator and Plan Participants

Abbott Laboratories Stock Retirement Plan

Opinion on the financial statements

We have audited the accompanying statements of net assets available for benefits of Abbott Laboratories Stock Retirement Plan (the “Plan”) as of December 31, 2020 and 2019, the related statement of changes in net assets available for benefits for the year ended December 31, 2020, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2020 and 2019, and the changes in net assets available for benefits for the year ended December 31, 2020 in conformity with accounting principles generally accepted in the United States of America.

Basis for opinion

These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plan is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Plan’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Field: Page; Sequence: 4; Options: NewSection; Value: 3

Field: Sequence; Type: Arabic; Name: PageNo 3 Field: /Sequence

Field: /Page

Supplemental information

The schedule of assets (held at end of year) as of December 31, 2020 (“supplemental information”) has been subjected to audit procedures performed in conjunction with the audit of the Plan’s financial statements. The supplemental information is the responsibility of the Plan’s management. Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental information. In forming our opinion on the supplemental information, we evaluated whether the supplemental information, including its form and content, is presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the financial statements as a whole.

/s/ Grant Thornton LLP

We have served as the Plan’s auditor since 2002.

Chicago, Illinois

June 28, 2021

Field: Page; Sequence: 5; Options: NewSection; Value: 4

Field: Sequence; Type: Arabic; Name: PageNo 4 Field: /Sequence

Field: /Page

Field: Split-Segment; Name: 2

Abbott Laboratories Stock Retirement Plan
STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS
December 31, 2020 and 2019
(Dollars in thousands)
2020 2019
Assets
Cash $ - $ 652
Investments, at fair value 12,978,506 10,950,124
Notes receivable from participants 88,523 89,236
Accrued interest and dividend income 956 1,431
Due from brokers 142,584 312,311
Total assets 13,210,569 11,353,754
Liabilities
Investments sold short, at fair value 35,036 176,943
Accrued investment expenses 381 340
Due to brokers 93,367 219,039
Total liabilities 128,784 396,322
NET ASSETS AVAILABLE FOR BENEFITS $ 13,081,785 $ 10,957,432

The accompanying notes are an integral part of these statements.

Field: Page; Sequence: 6; Options: NewSection; Value: 5

Field: Sequence; Type: Arabic; Name: PageNo 5 Field: /Sequence

Field: /Page

Abbott Laboratories Stock Retirement Plan
STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS
Year ended December 31, 2020
(Dollars in thousands)
Additions
Contributions
Employer $ 164,083
Participant 307,496
Rollovers 42,082
Total contributions 513,661
Investment income
Net appreciation in fair value of investments 2,186,827
Interest and dividends 117,551
Net investment income 2,304,378
Interest income on notes receivable from participants 4,061
Total additions 2,822,100
Deductions
Benefits paid to participants 698,368
Other expenses 291
Total deductions 698,659
Net increase before transfers 2,123,441
Transfers into Plan (Note A) 912
NET INCREASE 2,124,353
Net assets available for benefits
Beginning of year 10,957,432
End of year $ 13,081,785

The accompanying notes are an integral part of this statement.

Field: Page; Sequence: 7; Value: 5

Field: Sequence; Type: Arabic; Name: PageNo 6 Field: /Sequence

Field: /Page

Field: Split-Segment; Name: 3

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS

December 31, 2020 and 2019

NOTE A - DESCRIPTION OF THE PLAN

The following description of the Abbott Laboratories Stock Retirement Plan (the “Plan”) provides only general information. Participants should refer to the Plan document for a more complete description of the Plan’s provisions.

General

The Plan is intended to constitute a profit-sharing plan under Section 401(a) of the Internal Revenue Code of 1986, as amended (the “IRC”), with a cash or deferred arrangement under IRC Section 401(k), and a portion of the Plan is intended to constitute an employee stock ownership plan that meets the applicable requirements of IRC Sections 409 and 4975(e)(7). The Plan is subject to the Employee Retirement Income Security Act of 1974, as amended (“ERISA”).

In general, United States employees of Abbott Laboratories (“Abbott”) and selected participating subsidiaries and affiliates may, after meeting certain employment requirements, voluntarily participate in the Plan. Beginning March 2017, newly hired employees in certain specified Abbott divisions and business units became eligible to participate in the Plan under a different structure (“Abbott Green” employees).

Effective May 18, 2020, the Cephea Valve Technologies, Inc. 401(k) Plan merged with and into the Plan. Assets totaling approximately $912,000 were transferred into the Plan.

Alight Solutions serves as the record keeper of the Plan. The Northern Trust Company (“Custodian” or “Trustee”) serves as the Plan’s custodian and trustee.

Contributions and Vesting

Contributions to the Plan are paid to the Abbott Laboratories Stock Retirement Trust (“Trust”). The Trust is administered by the Trustee and an investment committee (the “Committee”).

Employees are eligible to commence participation in the Plan on any entry date following their date of hire. Eligible employees electing to participate contribute from 2% up to 25% of their eligible earnings, subject to certain limitations. Participants may choose to make their contributions from pretax earnings, after-tax earnings, or both. The Plan also permits Roth 401(k) contributions and has a Roth 401(k) conversion feature. Participants who have attained age 50 before the end of the Plan year and who are making the maximum pretax contributions are eligible to make catch-up contributions. Participants may elect to invest their contributions in any or all of the investment options available under the Plan, except for investment options closed to new contributions.

Field: Page; Sequence: 8; Options: NewSection; Value: 7

7

Field: /Page

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2020 and 2019

NOTE A - DESCRIPTION OF THE PLAN - Continued

Contributions and Vesting - Continued

Employer matching contributions to the Plan are made each payroll period based on the participating employee’s eligible earnings, unless the employee has elected to participate as a Freedom 2 Save Participant as described below. The employer matching contribution for the year ended December 31, 2020 was 5% of the participant’s eligible earnings if the participant elected to contribute at least 2% of eligible earnings to the Plan.

Effective as of August 1, 2018, participants may enroll in the Freedom 2 Save program in the Plan. A Freedom 2 Save participant who m akes qualified student loan repayments of at least 2% of eligible earnings may receive a Freedom 2 Save employer contribution of 5% of eligible earnings shortly after the end of the year. An enrolled Freedom 2 Save participant who makes elective deferrals to the Plan will not receive employer matching contributions each payroll period but instead may receive a true-up employer matching contribution shortly after the end of the year for any payroll period for which the participant makes elective deferrals and does not receive a Freedom 2 Save employer contribution. Freedom 2 Save employer contributions and true-up employer matching contributions are only made on behalf of Freedom 2 Save participants who meet program guidelines, and who either are employed or on a qualifying leave of absence at the end of the applicable Plan year or terminate employment due to death or qualifying disability during such Plan year.

Employer contributions are invested according to the participant’s investment elections.

Cash dividends on Abbott common shares are (1) paid in cash to the participants or beneficiaries, (2) paid to the Plan and distributed in cash to participants or beneficiaries no later than 90 days after the close of the Plan year for which paid, or (3) paid to the Plan and credited to the accounts in which shares are held, as elected by each participant or beneficiary in accordance with rules established by the administrator.

On January 1, 2013, Abbott separated into two publicly traded companies – Abbott and AbbVie Inc. ("AbbVie"). The separation of Abbott and AbbVie was a tax-free distribution where Abbott shareholders received one share of AbbVie stock for every share of Abbott held as of the close of business on December 12, 2012, the record date for the distribution. Participants who received AbbVie stock through this distribution may continue to hold the stock in their Plan accounts but may not make new contributions or transfer existing contributions or earnings to purchase AbbVie stock in the Plan; however, participants may elect to reinvest their AbbVie dividends in AbbVie stock. If no election is made, AbbVie dividends are invested in the Plan’s default investment option.

Participants may direct the Trustee to sell all or a portion of the Abbott and AbbVie common shares held in their accounts and reinvest the proceeds in any of the other available investment options.

Field: Page; Sequence: 9; Value: 7

8

Field: /Page

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2020 and 2019

NOTE A - DESCRIPTION OF THE PLAN - Continued

Contributions and Vesting - Continued

Participants are at all times fully vested in their own contributions and earnings thereon. Vesting in employer contributions and earnings thereon is based on the following vesting schedule:

Vesting
Service percentage
Less than two years 0 %
Two years or more 100 %

Abbott Green participants are also fully vested in employer contributions upon disability.

Non-vested portions of employer contributions and earnings thereon are forfeited as of an employee’s termination date. Forfeitures are used to (1) restore any forfeitures of participants who returned to service with Abbott within a given period of time, (2) pay Plan expenses and (3) reduce future employer contributions if terminated participants do not return to service within the given period of time. In 2020, forfeitures reduced Abbott’s employer contributions by approximately $1.4 million. Approximately $249,000 and $535,000 in forfeitures were available at the end of 2020 and 2019, respectively.

Distributions and In-Service Withdrawals

Following retirement, termination or death (or for some participants from merged-in plans, upon disability), participants or their beneficiaries may elect to receive a distribution in installments, in a single lump sum or in a partial lump sum. Participants may elect a direct rollover of their accounts. Also, upon termination, participants may elect to defer distribution to a future date but, after termination of employment, distribution must be made by the 1 st of April following the year the participant reaches age 72 (or age 70 ½, if reached prior to January 1, 2020 ) or, if earlier, the 31 st of December following the year in which the participant dies. Interest, dividends and other earnings will continue to accrue on such deferred amounts.

Prior to termination, participants are permitted to withdraw their after-tax contributions (a fter-tax contributions made on or after January 8, 2016 may be withdrawn from the Plan only after being held for two or more years) and rollover contributions (including Roth rollover accounts and merged-in plan rollover accounts) and, after age 59 ½, may also withdraw pretax contributions. Distributions are made in cash or, to the extent contained in the participant’s account, a participant may elect distribution of Abbott and AbbVie common shares, and in each case, subject to certain limitations.

Field: Page; Sequence: 10; Value: 7

9

Field: /Page

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2020 and 2019

NOTE A - DESCRIPTION OF THE PLAN - Continued

Receivable from Participants

Participants may convert their vested account balances into one or two loans to themselves. The borrowing may not exceed the lesser of the current market value of the assets allocated to their vested accounts or 50% of all of their Plan accounts up to $50,000, subject to IRC limitations and restrictions. Participants pay interest on such borrowings at the prime rate in effect at the time the participant loan is made. Loans must be repaid within five years (or by the employee’s anticipated retirement date, if sooner) unless the loan is used for the purchase of the primary residence of the employee, in which case the repayment period can be extended to a period of fifteen years (or until the employee’s anticipated retirement date, if sooner). Repayment is made through periodic payroll deductions or by sending in payments, but a loan may be repaid in a lump sum at any time. Post-termination loan repayments are permitted. For employees whose account is distributed during the repayment period, the balance of the outstanding loan is netted from their Plan distribution.

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Accounting

The financial statements have been prepared using the accrual basis of accounting.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and changes therein, and disclosure of contingent assets and liabilities. Actual results may differ from those estimates.

Investment Valuation

The Plan offers a variety of investment options to participants. Certain investment options are structured as separately managed accounts; therefore, the Plan owns the individual investment holdings within the separately managed accounts and reflects them within the investments of the Plan.

The Plan uses the following methods and significant assumptions to estimate the fair value of investments:

Common stock, mutual funds, REITs and futures contracts - Valued at the published market price per share or unit multiplied by the number of respective shares or units held.

Field: Page; Sequence: 11; Value: 7

10

Field: /Page

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2020 and 2019

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Investment Valuation - Continued

Collective trust funds and Private 40-Act mutual funds - Valued at the net asset value (“NAV”) provided by the administrator of the fund. The NAV is used as a practical expedient to estimate fair value. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. Participants are permitted to make redemptions from the funds on a daily basis. Certain funds require five days’ notice for a Plan level redemption. The Private 40-Act mutual funds agree to redeem shares solely in cash up to the lesser of $250,000 or 1% of the fund’s net assets during any 90-day period for any one shareholder. In consideration of the best interests of the remaining shareholders, the Private 40-Act mutual funds reserve the right to pay any redemption proceeds exceeding this amount in whole or in part by a distribution in kind of securities held by the funds in lieu of cash. It is highly unlikely that shares would ever be redeemed in kind.

Corporate debt and g overnment debt - Valued at the published market price or prices obtained from independent financial services industry-recognized vendors multiplied by the number of respective units held. Prices obtained from vendors are on the basis of bid or mid evaluations in accordance to a region’s market convention, using factors which include but are not limited to market quotations, yields, maturities, and the bond’s terms and conditions. Proprietary methods are used to arrive at the evaluated price, which represent the price a dealer would pay for a security.

Certificate of deposit - Valued at amortized cost, which approximates fair value given the instruments’ short duration of less than 130 days.

Futures contracts

One of the investment options structured as a separately managed account uses futures contracts as part of its investment strategy. A futures contract represents a commitment for the future purchase or sale of an asset or index at a specified price on a specified date. Futures contracts are exchange-traded and settle daily. Upon entering into the contracts, the investment manager of the separately managed account is required to deposit, either in cash or securities, an amount equal to a certain percentage of the notional value of the contract. Subsequent payments are then made or received by the Plan, depending on the daily fluctuation in the value of the underlying contracts.

As of December 31, 2020 and 2019, the Plan held futures contracts with a notional amount of approximately $2.2 million and $2.3 million, respectively. Notional amounts do not quantify risk or represent assets or liabilities of the Plan, but are used in the calculation of the cash settlements under the contracts. The fair value of these derivative contracts was not material at December 31, 2020 and 2019. Changes in fair value are accounted for as investment income within net appreciation in fair value of investments and totaled approximately $456,000 for the year ended December 31, 2020.

Field: Page; Sequence: 12; Value: 7

11

Field: /Page

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2020 and 2019

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Investment Valuation - Continued

Short sales

One of the investment options structured as a separately managed account utilizes short sales as part of its investment strategy. Short sales are transactions in which the separately managed account sells an investment it does not own in anticipation of a decline in value of that investment. To complete the transaction, the separately managed account must borrow the investment to make delivery to the buyer. The separately managed account is obligated to replace the investment borrowed by purchasing the investment at market price at the time of replacement. The price at such time may be more or less than the price at which the investment was sold by the separately managed account. When an investment is sold short, a decrease in the value of the investment will be recognized as a gain and an increase in the value of the investment will be recognized as a loss.

The following tables summarize the basis used to measure investment assets and liabilities at fair value at December 31, 2020 and 2019 (dollars in thousands):

2020 Basis of Fair Value Measurement — Quoted Prices in Active Markets Significant Other Observable Inputs Significant Unobservable Inputs Measured at NAV Total
Assets - Investments:
Common stock $ 4,819,600 $ - $ - $ - $ 4,819,600
Mutual funds 96,224 - - - 96,224
REITs 18,379 - - - 18,379
Collective trust funds - - - 7,240,401 7,240,401
Corporate debt - 242,622 - - 242,622
Government debt - 146,837 - - 146,837
Certificate of deposit - 4,509 - - 4,509
Private 40-Act mutual funds - - - 409,934 409,934
Total investments at fair value $ 4,934,203 $ 393,968 $ - $ 7,650,335 $ 12,978,506
2020 Basis of Fair Value Measurement — Quoted Prices in Active Markets Significant Other Observable Inputs Significant Unobservable Inputs Measured at NAV Total
Liabilities - Investments sold short:
Government debt $ - $ 35,036 $ - $ - $ 35,036
Total investments sold short at fair value $ - $ 35,036 $ - $ - $ 35,036

Field: Page; Sequence: 13; Value: 7

12

Field: /Page

Field: Split-Segment; Name: 4

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2020 and 2019

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Investment Valuation - Continued

Basis of Fair Value Measurement
Quoted Significant
Prices in Other Significant
Active Observable Unobservable Measured at
2019 Markets Inputs Inputs NAV Total
Assets - Investments:
Common stock $ 4,059,697 $ - $ - $ - $ 4,059,697
Mutual funds 96,694 - - - 96,694
REITs 29,638 - - - 29,638
Collective trust funds - - - 5,972,632 5,972,632
Corporate debt - 250,580 - - 250,580
Government debt - 299,689 - - 299,689
Certificate of deposit - 3,106 - - 3,106
Private 40-Act mutual funds - - - 238,088 238,088
Total investments at fair value $ 4,186,029 $ 553,375 $ - $ 6,210,720 $ 10,950,124
Basis of Fair Value Measurement
Quoted Significant
Prices in Other Significant
Active Observable Unobservable Measured at
2019 Markets Inputs Inputs NAV Total
Liabilities - Investments sold short:
Government debt $ - $ 176,943 $ - $ - $ 176,943
Total investments sold short at
fair value $ - $ 176,943 $ - $ - $ 176,943

The Private 40-Act mutual funds are not direct filing entities. These funds invest in fixed income instruments of varying maturities. The investment objective of one fund is to seek maximum current income and the other is to seek maximum total return, both being consistent with preservation of capital and liquidity.

Notes Receivable from Participants

Notes receivable from participants are measured at their unpaid balance plus any accrued but unpaid interest. Delinquent loans are reclassified as distributions based upon the terms of the Plan. No allowance for credit losses has been recorded as of December 31, 2020 or 2019.

Field: Page; Sequence: 14; Options: NewSection; Value: 13

Field: Sequence; Type: Arabic; Name: PageNo 13 Field: /Sequence

Field: /Page

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2020 and 2019

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Income Recognition

Purchases and sales of securities are recorded on a trade-date basis. Interest income is recorded on an accrual basis. Dividends are recorded on the ex-dividend date. Net realized and unrealized appreciation/depreciation is recorded in the accompanying statement of changes in net assets available for benefits as net appreciation in fair value of investments.

Administrative Expenses

Participants are charged transaction fees for loan processing and commissions on purchases and sales of Abbott shares and sales of AbbVie stock. Investment fees for mutual funds, REITs, collective trusts, and managed accounts are charged against the net assets of the respective fund. Abbott pays other record-keeping and administration fees, where applicable.

Payment of Benefits

Benefits are recorded when paid.

NOTE C - INVESTMENTS

Distributions of Abbott common shares and conversions of participants’ common share account balances to participant loans or other investment options are recorded at fair market value.

A summary of Abbott common share data as of December 31, 2020 and 2019 is presented below:

2020 2019
Abbott common shares, 27,617,036 and 28,371,110 shares, respectively (dollars in thousands) $ 3,023,789 $ 2,464,315
Market value per share $ 109.49 $ 86.86

Field: Page; Sequence: 15; Value: 13

Field: Sequence; Type: Arabic; Name: PageNo 14 Field: /Sequence

Field: /Page

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2020 and 2019

NOTE D - RELATED-PARTY AND PARTY-IN-INTEREST TRANSACTIONS

The Plan holds units of collective trust funds managed by the Trustee and shares of the Trustee’s common stock. A significant portion of the Plan’s assets is invested in Abbott common shares. These transactions qualify as party-in-interest transactions; however, they are exempt from the prohibited transaction rules under ERISA. During 2020, the Plan received $40 million in common stock dividends from Abbott.

Participants pay fees to the recordkeeper for loan transaction processing and for commissions on purchases and sales of Abbott shares and sales of AbbVie stock. These transactions qualify as permitted party-in-interest transactions.

NOTE E - PLAN TERMINATION

The Plan may be terminated at any time by Abbott upon written notice to the Trustee and Committee. All participants’ account balances would become fully vested upon Plan termination. Upon termination of the Plan, distributions of each participant’s share in the Trust, as determined by the terms of the Plan, would be made to each participant. At the present time, Abbott has no intention of terminating the Plan.

NOTE F - TAX STATUS

The Internal Revenue Service (“IRS”) has determined and informed Abbott by a letter dated May 19, 2017, that the Plan and related Trust are designed in accordance with applicable sections of the IRC. The Plan has been amended since the applicable date of the determination letter. However, the Plan administrator believes that the Plan is designed and is currently being operated, in all material respects, in accordance with the applicable requirements of the IRC.

Accounting principles generally accepted in the United States of America require Plan management to evaluate tax positions taken by the Plan and recognize a tax liability if the organization has taken an uncertain position that more likely than not would not be sustained upon examination by the IRS or other applicable taxing authorities. The Plan administrator has analyzed the tax positions taken by the Plan, and has concluded that as of December 31, 2020 and 2019, there are no uncertain positions taken or expected to be taken that would require recognition of a liability or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions. There are currently no audits in progress.

Field: Page; Sequence: 16; Value: 13

Field: Sequence; Type: Arabic; Name: PageNo 15 Field: /Sequence

Field: /Page

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2020 and 2019

NOTE G – RISKS AND UNCERTAINTIES

In general, the investments provided by the Plan are exposed to various risks, such as interest rate, credit and overall market volatility risks. Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect participant accounts and the amounts reported in the statements of net assets available for benefits.

In March 2020, the World Health Organization declared COVID-19 a pandemic and recommended containment and mitigation measures worldwide. The pandemic is ongoing and has caused significant volatility and uncertainty in U.S. and international financial markets. The volatility in the markets has not resulted in a material change in the fair value of the Plan’s investments since December 31, 2020; however, the ultimate impact of COVID-19 on the Company, the Plan, and global financial markets will depend on future developments that are difficult to assess or predict, and the potential impact to the Plan’s net assets available for benefits and changes in net assets available for benefits is uncertain.

NOTE H - SUBSEQUENT EVENTS

Management of the Plan has evaluated subsequent events from December 31, 2020 through the date these financial statements were issued. Management of the Plan is not aware of any subsequent events that require recognition or additional disclosure in these financial statements.

Field: Page; Sequence: 17; Value: 13

Field: Sequence; Type: Arabic; Name: PageNo 16 Field: /Sequence

Field: /Page

SUPPLEMENTAL SCHEDULE

Field: Page; Sequence: 18

Field: /Page

Field: Split-Segment; Name: 5

Abbott Laboratories Stock Retirement Plan
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)
December 31, 2020
(Dollars in thousands)
Identity of party involved/ Current
Description of asset/ Rate/ Maturity Cost (a) value
Common stock - employer securities
*ABBOTT LABORATORIES, common shares $ 3,023,789
Common stock
1ST CTZNS BANCSHARES INC CL A 119
2U INC COM 58
5TH 3RD BANCORP 626
ABBVIE INC. 1,623,860
ACADIA HEALTHCARE CO INC COM 141
ACCELERON PHARMA INC COM 13
ACUITY BRANDS INC COM 139
ADT INC DEL COM 39
ADVANCE AUTO PTS INC COM 323
AECOM 245
AES CORP COM 496
AFFILIATED MANAGERS GROUP INC COM STK 141
AGCO CORP COM 205
AGILENT TECHNOLOGIES INC COM 1,060
AGIOS PHARMACEUTICALS INC COM 77
AIR LEASE CORP CL A 152
AKAMAI TECHNOLOGIES INC COM STK 95
ALASKA AIR GROUP INC COM 201
ALBEMARLE CORP COM 498
ALBERTSONS COS INC CL A 16
ALEXION PHARMACEUTICALS INC COM 889
ALKERMES PLC SHS 101
ALLEGHANY CORP DEL COM 235
ALLEGION PLC COMMON STOCK 121
ALLEGRO MICROSYSTEMS INC 11
ALLIANCE DATA SYS CORP COM 113
ALLIANT ENERGY CORP COM 405
ALLISON TRANSMISSION HOLDING 54
ALLY FINL INC COM 425
AMCOR PLC 497
AMDOCS 296
AMER FINL GROUP INC OH COM STK 194
AMERCO COM 130
AMEREN CORP COM 607
AMERICAN AIRLINES INC COM 269
AMERICAN NATL GROUP INC COM 22
AMERICAN WELL CORP COM CL A 8
AMERICAN WTR WKS CO INC NEW COM 885
AMERIPRISE FINL INC COM 724
AMERISOURCEBERGEN CORP COM 238
AMETEK INC NEW COM 883
AMPHENOL CORP NEW CL A 492
ANTERO MIDSTREAM CORPORATION 71
APA CORP 172
APARTMENT COM 25
APARTMENT INCOME REIT CORP COM 180
APOLLO GLOBAL MGMT INC 136
APTARGROUP INC COM 278
APTIV PLC COM 1,104
ARAMARK COM 275

Field: Page; Sequence: 19; Options: NewSection; Value: 18

Field: Sequence; Type: Arabic; Name: PageNo 18 Field: /Sequence

Field: /Page

Abbott Laboratories Stock Retirement Plan
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued
December 31, 2020
(Dollars in thousands)
Identity of party involved/ Current
Description of asset/ Rate/ Maturity Cost (a) value
Common stock - continued
ARCH CAPITAL GROUP COM STK 446
ARCHER-DANIELS-MIDLAND CO COM 883
ARDAGH GROUP S A ARDAGH GROUP S A 10
ARISTA NETWORKS INC COM 99
ARMSTRONG WORLD INDS INC NEW COM STK 72
ARRAY TECHNOLOGIES INC COM 73
ARROW ELECTR INC COM 228
ASHLAND GLOBAL HLDGS INC COM 142
ASPEN TECHNOLOGY INC COM 20
ASSOCTD BANC-CORP COM 79
ASSURANT INC COM 250
ASSURED GUARANTY LTD COMMON STK 74
ATHENE HOLDING LTD 152
ATMOS ENERGY CORP COM 374
AUTONATION INC COM 126
AUTOZONE INC COM 356
AVANGRID INC COM 82
AVERY DENNISON CORP COM 241
AVNET INC COM 110
AXALTA COATING SYSTEMS LTD 193
AXIS CAPITAL HOLDINGS LTD 123
AZEK CO INC CL A 69
BAKER HUGHES CO 431
BALL CORP COM 61
BANK OZK COM 122
BERKELEY LTS INC COM 16
BERKLEY W R CORP COM 297
BERRY GLOBAL GROUP INC 158
BEST BUY INC COM STK 596
BEYOND MEAT INC 42
BIGCOMMERCE HLDGS INC 3
BIO RAD LABS INC CL A 390
BIOMARIN PHARMACEUTICAL INC 48
BIO-TECHNE CORP COM 24
BK HAW CORP COM 97
BLOCK H & R INC COM 29
BLUEBIRD BIO INC COM 50
BOK FINL CORP COM NEW 69
BORG WARNER INC COM 258
BRIGHT HORIZONS FA COM 102
BRIGHTHOUSE FINL INC COM 99
BROWN & BROWN INC COM 332
BROWN FORMAN CORP CL A 15
BROWN-FORMAN INC CL B NON-VTG COM 69
BRUKER CORP 103
BRUNSWICK CORP COM 194
BUNGE LTD 283
BURLINGTON STORES INC COM 58
BWX TECHNOLOGIES INC COM 67
C H ROBINSON WORLDWIDE INC COM 329
CABOT CORP COM 80
CABOT OIL & GAS CORP COM 205
CACI INTL INC CL A 167

Field: Page; Sequence: 20; Value: 18

Field: Sequence; Type: Arabic; Name: PageNo 19 Field: /Sequence

Field: /Page

Abbott Laboratories Stock Retirement Plan
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued
December 31, 2020
(Dollars in thousands)
Identity of party involved/ Current
Description of asset/ Rate/ Maturity Cost (a) value
Common stock - continued
CAMPBELL SOUP CO COM 147
CAPRI HOLDINGS LTD 191
CARLISLE COMPANIES INC COM 257
CARLYLE GROUP INC COM 106
CARMAX INC COM 453
CARNIVAL CORP COM PAIRED 331
CARRIER GLOBAL CORPORATION COM 663
CARTER INC 130
CASEYS GEN STORES INC COM 207
CATALENT INC COM 539
CBOE GLOBAL MARKETS INC 245
CBRE GROUP INC CL A 661
CDK GLOBAL INC COM 172
CELANESE CORP 477
CENTERPOINT ENERGY INC COM 342
CERIDIAN HCM HLDG INC COM 114
CF INDS HLDGS INC COM 266
CHANGE HEALTHCARE INC COM 38
CHARLES RIV LABORATORIES INTL INC COM 44
CHEMOURS CO COM 131
CHOICE HOTELS INTL INC COM 119
CIENA CORP COM NEW 260
CIMAREX ENERGY CO COM 120
CIN FNCL CORP COM 411
CINTAS CORP COM 115
CIRRUS LOGIC INC COM 147
CITIZENS FINL GROUP INC COM 485
CITRIX SYS INC COM 367
CLEAN HBRS INC COM 126
CLOROX CO COM 239
CMS ENERGY CORP COM 550
CNA FNCL CORP COM 34
COHERENT INC COM 20
COLFAX CORP 122
COLUMBIA SPORTSWEAR CO COM 80
COMERICA INC COM 250
COMM BANCSHARES INC COM 223
COMMSCOPE HLDG CO INC COM 78
CONAGRA BRANDS INC COM 558
CONCENTRIX CORP 132
CONOCOPHILLIPS 361
CONS EDISON INC COM 765
CONTINENTAL RES INC COM 38
COOPER COS INC COM 496
COPA HOLDINGS SA COM STK 78
CORELOGIC INC-W/I COM STK 177
CORNING INC COM 854
CORTEVA INC COM 919
COTY INC COM CL A 63
CRANE CO COM 121
CREDIT ACCEP CORP MICH COM 103
CREE INC COM 369
CROWDSTRIKE HLDGS INC CL A 284

Field: Page; Sequence: 21; Value: 18

Field: Sequence; Type: Arabic; Name: PageNo 20 Field: /Sequence

Field: /Page

Abbott Laboratories Stock Retirement Plan
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued
December 31, 2020
(Dollars in thousands)
Identity of party involved/ Current
Description of asset/ Rate/ Maturity Cost (a) value
Common stock - continued
CROWN HLDGS INC COM 370
CULLEN / FROST BANKERS INC COM 157
CUMMINS INC 1,060
CURTISS WRIGHT CORP COM 152
D R HORTON INC COM 720
DARDEN RESTAURANTS INC COM 494
DATTO HLDG CORP COM 11
DAVITA INC COM 233
DELTA AIR LINES INC DEL COM NEW 811
DENTSPLY SIRONA INC COM 364
DEVON ENERGY CORP 105
DEVON ENERGY CORP NEW COM 194
DIAMONDBACK ENERGY INC COM 245
DICKS SPORTING GOODS INC 112
DISCOVER FINL SVCS COM STK 877
DISCOVERY INC - A 152
DISCOVERY INC COM 254
DISH NETWORK CORP CL A COM STK 249
DOLBY LABORATORIES INC CL A COM STK 171
DOLLAR TREE INC COM STK 417
DONALDSON INC COM 204
DOVER CORP COM 577
DTE ENERGY CO COM 744
DUCK CREEK TECHNOLOGIES INC COM 5
DUN & BRADSTREET HLDGS INC COM 35
DXC TECHNOLOGY CO COM 210
EAGLE MATLS INC COM 135
EAST WEST BANCORP INC COM 230
EASTMAN CHEM CO COM 433
EATON VANCE CORP 242
ECHOSTAR CORPORATION 32
EDISON INTL COM 710
ELANCO ANIMAL HEALTH INC COM 439
ELEMENT SOLUTION INC COM 123
ENCOMPASS HEALTH CORP COM 143
ENERGIZER HLDGS INC NEW COM 18
ENTEGRIS INC COM 25
ENTERGY CORP NEW COM 640
ENVISTA HLDGS CORP COM 174
EQT CORP COM 113
EQUIFAX INC COM 194
EQUITABLE HLDGS INC COM 322
EQUITRANS MIDSTREAM CORP COM NPV WI 96
ERIE INDTY CO CL A 86
ESSENTIAL UTILS INC COM 337
EURONET WORLDWIDE INC COM 234
EVERCORE INC 139
EVEREST RE GROUP COM 289
EVERGY INC COM NPV 401
EVERSOURCE ENERGY COM 940
EXACT SCIENCES CORP COM 82
EXELIXIS INC COM STK 126
EXPEDIA GROUP INC COM 501

Field: Page; Sequence: 22; Value: 18

Field: Sequence; Type: Arabic; Name: PageNo 21 Field: /Sequence

Field: /Page

Abbott Laboratories Stock Retirement Plan
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued
December 31, 2020
(Dollars in thousands)
Identity of party involved/ Current
Description of asset/ Rate/ Maturity Cost (a) value
Common stock - continued
EXPEDITORS INTL WASH INC COM 197
EXTENDED STAY AMER INC 85
F N B CORP PA COM 96
F5 NETWORKS INC COM STK 337
FASTENAL CO COM 164
FIDELITY NATL FINL INC 337
FIREEYE INC COM 127
FIRST AMERN FINL CORP COM STK 180
FIRST HAWAIIAN INC COM 99
FIRST HORIZON CORPORATION COM 219
FIRST REP BK SAN FRANCISCO CALIF NEW COM 806
FIRST SOLAR INC COM 292
FIRSTENERGY CORP COM 523
FLOWERS FOODS INC COM 143
FLOWSERVE CORP COM 155
FMC CORP COM (NEW) 379
FOOT LOCKER INC COM 135
FORD MTR CO DEL COM 1,085
FORTIVE CORP COMMON STOCK 673
FORTUNE BRANDS HOME & SEC INC COM 371
FOX CORP CL A 305
FOX CORP CL B 141
FREEPORT-MCMORAN INC 1,194
FRKLN RES INC COM 218
FRONTDOOR INC COM 114
FTI CONSULTING INC COM 121
GALLAGHER ARTHUR J & CO COM 746
GAP INC COM 118
GARMIN LTD COMMON STOCK 571
GATES INDL CORP PL 15
GENERAC HLDGS INC COM STK 38
GENPACT LIMITED 152
GENTEX CORP COM 265
GENUINE PARTS CO COM 447
GLOBE LIFE INC COM 307
GLOBUS MED INC CL A 157
GOHEALTH INC CL A 17
GRACE W R & CO DEL NEW COM STK 63
GRACO INC COM 189
GRAFTECH INTL LTD COM 24
GRAHAM HLDGS CO COM CL B COM 69
GRAINGER W W INC COM 156
GRAND CANYON ED INC COM STK 140
GRAPHIC PACKAGING HLDG CO COM STK 109
GROCERY OUTLET HLDG CORP COM 41
GRUBHUB INC COM 199
GUIDEWIRE SOFTWARE INC COM 279
HAEMONETICS CORP MASS COM 13
HAIN CELESTIAL GROUP INC COM 104
HALLIBURTON CO COM 528
HANESBRANDS INC COM STK 163
HANOVER INS GROUP INC COM 134
HARLEY DAVIDSON COM 181

Field: Page; Sequence: 23; Value: 18

Field: Sequence; Type: Arabic; Name: PageNo 22 Field: /Sequence

Field: /Page

Abbott Laboratories Stock Retirement Plan
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued
December 31, 2020
(Dollars in thousands)
Identity of party involved/ Current
Description of asset/ Rate/ Maturity Cost (a) value
Common stock - continued
HARTFORD FINL SVCS GROUP INC COM 552
HASBRO INC COM 379
HAWAIIAN ELEC INDS INC COM 122
HEICO CORP NEW CL A 57
HEICO CORP NEW COM 36
HELMERICH & PAYNE INC COM 78
HENRY SCHEIN INC COMMON STOCK 303
HERBALIFE NUTRITION LTD COM STK 120
HERSHEY COMPANY COM STK 165
HESS CORP COM STK 462
HEWLETT PACKARD ENTERPRISE CO COM 487
HEXCEL CORP NEW COM 130
HILL-ROM HLDGS INC COM STK 186
HILTON WORLDWIDE HLDGS INC COM 969
HOLLYFRONTIER CORP COM 125
HOLOGIC INC COM 181
HORIZON THERAPEUTICS PLC 34
HORMEL FOODS CORP COM 409
HOWARD HUGHES CORP COM STOCK 100
HOWMET AEROSPACE INC COM 354
HP INC COM 1,070
HUBBELL INC COM 267
HUNT J B TRANS SVCS INC COM 269
HUNTINGTON BANCSHARES INC COM 406
HUNTINGTON INGALLS INDS INC COM 190
HUNTSMAN CORP COM STK 162
HYATT HOTELS CORP COM CL A 84
IAA SPINCO INC 214
ICU MED INC COM 99
IDACORP INC COM 155
IDEX CORP COM 473
IHS MARKIT LTD COM 518
INGERSOLL RAND INC COM 503
INGREDION INC COM 170
INTEGRA LIFESCIENCES HLDG CORP COM DESP 145
INTERACTIVE BROKERS GROUP INC CL COM 144
INTERPUBLIC GROUP COMPANIES INC COM 289
INTL FLAVORS & FRAGRANCES INC COM 366
INTL PAPER CO COM 624
INVESCO LTD COM STK 212
IONIS PHARMACEUTICALS INC COM 121
IPG PHOTONICS CORP COM 239
IQVIA HLDGS INC COM 675
ITT INC COM 214
JABIL INC COM 163
JACK HENRY & ASSOC INC COM 86
JACOBS ENGR GROUP INC COM 436
JAMF HLDG CORP COM 15
JAZZ PHARMACEUTICALS PLC 287
JEFFERIES FINL GROUP INC COM 164
JETBLUE AWYS CORP COM 144
JFROG LTD COM 3
JOHNSON CTLS INTL PLC COM 1,072

Field: Page; Sequence: 24; Value: 18

Field: Sequence; Type: Arabic; Name: PageNo 23 Field: /Sequence

Field: /Page

Field: Split-Segment; Name: 6

Abbott Laboratories Stock Retirement Plan
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued
December 31, 2020
(Dollars in thousands)
Identity of party involved/ Description of asset/ Rate/ Maturity
Common stock - continued
JONES LANG LASALLE INC COM STK 246
JUNIPER NETWORKS INC COM 234
KELLOGG CO COM 324
KEMPER CORP DEL COM 154
KEYCORP NEW COM 507
KEYSIGHT TECHNOLOGIES INC COM 523
KIRBY CORP COM 99
KKR & CO INC CL A 701
KNIGHT-SWIFT TRANSN HLDGS INC 168
KOHLS CORP COM 206
KROGER CO COM 777
KS CY SOUTHN 601
L BRANDS INC COM 267
LAB CORP AMER HLDGS COM NEW 596
LAMAR ADVERTISING CO NEW CL A 230
LAMB WESTON HLDGS INC COM 277
LANDSTAR SYS INC COM 30
LAZARD LTD CL A 134
LEAR CORP COM NEW 299
LEGGETT & PLATT INC COM 188
LEIDOS HLDGS INC COM 402
LEMONADE INC COM 50
LENDINGTREE INC NEW COM 4
LENNAR CORP CL A 657
LENNAR CORP CL B 29
LENNOX INTL INC COM 297
LESLIES INC COM 21
LIBERTY BROADBAND CORP COM SER A 125
LIBERTY BROADBAND CORP COM SER C 800
LIBERTY MEDIA CORP DEL COM SER A SIRIUSXM GROUP 101
LIBERTY MEDIA CORP DEL COM SER A FORMULAONE COM 30
LIBERTY MEDIA CORP DEL COM SER C FORMULAONE 264
LIBERTY MEDIA CORP DEL COM SER C SIRIUSXM GROUP 215
LINCOLN ELEC HLDGS INC COM 122
LINCOLN NATL CORP COM 273
LIONS GATE ENTMT CORP CL B NON VTG 38
LIONS GATE ENTMT CORP VOTING SHARES CL A 22
LITTELFUSE INC COM 193
LKQ CORP COM LKQ CORP 339
LOEWS CORP COM 331
LPL FINL HLDGS INC COM 238
LUMEN TECH INC 335
LUMENTUM HLDGS INC COM 204
LYFT INC CL A 384
LYONDELLBASELL IND N V 743
M & T BK CORP COM 520
MACQUARIE INFRASTRUCTURE CORP 89
MADISON SQUARE GARDEN ENTMT CORP CL A 62
MADISON SQUARE GARDEN SPORTS CORP 110
MANHATTAN ASSOCS INC COM 23
MANPOWERGROUP INC 168
MARATHON OIL CORP COM 169
MARATHON PETE CORP COM 847

Field: Page; Sequence: 25; Options: NewSection; Value: 24

Field: Sequence; Type: Arabic; Name: PageNo 24 Field: /Sequence

Field: /Page

Abbott Laboratories Stock Retirement Plan
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued
December 31, 2020
(Dollars in thousands)
Identity of party involved/ Description of asset/ Rate/ Maturity
Common stock - continued
MARKEL CORP HOLDING CO COM 439
MARTIN MARIETTA MATLS INC COM 564
MARVELL TECHNOLOGY 1,003
MASCO CORP COM 455
MATTEL INC COM STOCK 78
MAXIM INTEGRATED PRODS INC COM 502
MC CORMICK & CO INC COM NON-VTG 328
MCAFEE CORP CL A 6
MCKESSON CORP 231
MDU RES GROUP INC COM 169
MERCURY GEN CORP NEW COM 45
MERCURY SYSTEMS INC 28
METTLER-TOLEDO INTL INC COM 51
MGIC INVT CORP WIS COM 136
MGM RESORTS INTERNATIONAL COM 472
MICROCHIP TECHNOLOGY INC COM 272
MIDDLEBY CORP COM 229
MKS INSTRS INC COM 65
MOHAWK INDS INC COM 264
MOLINA HEALTHCARE INC COM 131
MOLSON COORS BEVERAGE COMPANY COM 253
MORNINGSTAR INC COM STK 26
MOSAIC CO/THE 249
MOTOROLA SOLUTIONS INC 821
MSA SAFETY INC COM 137
MSC INDL DIRECT INC CL A COM 121
MURPHY OIL CORP COM 56
N V R INC COM 396
NASDAQ INC 478
NATIONAL 167
NATIONAL INSTRS CORP COM 182
NATL FUEL GAS CO COM 116
NCINO INC COM 3
NCR CORP COM 153
NEKTAR THERAPEUTICS COM 96
NETAPP INC COM STK 216
NEW YORK CMNTY BANCORP INC COM 154
NEW YORK TIMES CO CL A 271
NEWELL BRANDS INC COM 262
NEWMARKET CORP COM 16
NEWS CORP COM CL A 225
NEWS CORP COM CL B 69
NEXSTAR MEDIA GROUP INC CL A 51
NIELSEN HOLDINGS PLC COMSTK 239
NISOURCE INC COM 278
NORDSON CORP COM 69
NORDSTROM INC COM 109
*NORTHERN TR CORP COM 564
NORWEGIAN CRUISE LINE HLDGS LTD 251
NRG ENERGY INC COM NEW 192
NU SKIN ENTERPRISES INC CL A 90
NUANCE COMMUNICATIONS INC COM 390
NUCOR CORP COM 511

Field: Page; Sequence: 26; Value: 24

Field: Sequence; Type: Arabic; Name: PageNo 25 Field: /Sequence

Field: /Page

Abbott Laboratories Stock Retirement Plan
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued
December 31, 2020
(Dollars in thousands)
Identity of party involved/ Description of asset/ Rate/ Maturity
Common stock - continued
NVENT ELECTRIC PLC COM 116
OAK STR HEALTH INC COM 21
OCCIDENTAL PETROLEUM CORP 458
OGE ENERGY CORP COM 205
OLD DOMINION FREIGHT LINE INC COM 84
OLD REP INTL CORP COM 179
OLIN CORP COM 113
OLLIES BARGAIN OUTLET HLDGS INC COM 17
OMNICOM GROUP INC COM 422
ON SEMICONDUCTOR CORP COM 423
ONEMAIN HLDGS INC COM 102
ONEOK INC COM STK 542
OSHKOSH CORPORATION 187
OTIS WORLDWIDE CORP COM 872
OWENS CORNING NEW COM STK 261
PACCAR INC COM 926
PACKAGING CORP AMER COM 412
PACWEST BANCORP DEL COM 96
PARKER-HANNIFIN CORP COM 1,104
PARSLEY ENERGY 138
PAYCHEX INC COM 202
PEGASYSTEMS INC COM 18
PELOTON INTERACTIVE INC 922
PENSKE AUTOMOTIVE GROUP INC COM STK 61
PENTAIR PLC COM 282
PEOPLES UTD FINL INC COM 176
PERKINELMER INC COM 410
PERRIGO COMPANY LIMITED COM 197
PG& E CORP COM 521
PILGRIMS PRIDE CORP 22
PINNACLE FINL PARTNERS INC COM 152
PINNACLE W. CAP CORP COM 286
PINTEREST INC CL A 145
PIONEER NAT RES CO COM 596
PLANET FITNESS INC CL A 84
POLARIS INC 160
POPULAR INC COM 150
POST HLDGS INC COM STK 207
PPD INC COM 27
PPG IND INC COM 1,077
PPL CORP COM 686
PRA HEALTH SCIENCES INC COM 36
PREMIER INC CL A 132
PRIMERICA INC COM 63
PRINCIPAL FINL GROUP INC COM STK 428
PROSPERITY BANCSHARES INC COM 199
PRUDENTIAL FINL INC COM 985
PUB SERVICE ENTERPRISE GROUP INC COM 932
PULTE GROUP INC 367
PURE STORAGE INC CL A 76
PVH CORP COM 212
QIAGEN NV 373
QORVO INC COM 606

Field: Page; Sequence: 27; Value: 24

Field: Sequence; Type: Arabic; Name: PageNo 26 Field: /Sequence

Field: /Page

Abbott Laboratories Stock Retirement Plan
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued
December 31, 2020
(Dollars in thousands)
Identity of party involved/ Description of asset/ Rate/ Maturity
Common stock - continued
QUANTA SVCS INC COM 253
QUEST DIAGNOSTICS INC COM 502
QURATE RETAIL INC 134
RALPH LAUREN CORP CL A 157
RAYMOND JAMES FNCL INC COM STK 369
REALPAGE INC 26
REATA PHARMACEUTICALS INC CL A 10
REGAL BELOIT CORP 155
REGIONS FINL CORP NEW COM 493
REINSURANCE GROUP AMER INC COM NEW STK 246
RELIANCE STL & ALUM CO COM 245
RENAISSANCE RE HLDGS LTD COM 179
REPUBLIC SVCS INC COM 638
REYNOLDS CONSUMER PRODS INC COM 35
ROBERT HALF INTL INC COM 224
ROCKWELL AUTOMATION 471
ROLLINS INC COM 34
ROYAL CARIBBEAN GROUP COM STK 431
ROYAL GOLD INC COM STK 63
ROYALTY PHARMA PLC COM 96
RPM INTL INC 61
RYDER SYS INC COM 104
S.W. AIRL CO COM 869
SABRE CORP COM 117
SAGE THERAPEUTICS INC COM 132
SANTANDER CONSUMER USA HLDGS INC COM 53
SCHNEIDER NATL INC WIS CL B 39
SCIENCE APPLICATIONS INTL CORP NEW COM 154
SCOTTS MIRACLE-GRO CLASS'A'COM NPV 17
SEABOARD CORP DEL COM 24
SEALED AIR CORP NEW COM STK 229
SEI INVTS CO COM 202
SENSATA TECHNOLOGIES B V HOLDING 262
SERVICE CORP INTL COM 259
SIGNATURE BK NY N Y COM 226
SILGAN HLDGS INC COM 93
SIRIUS XM HLDGS INC COM 96
SIX FLAGS ENTMT CORP NEW COM 83
SKECHERS U S A INC CL A 155
SKYWORKS SOLUTIONS INC COM 806
SLM CORP COM 115
SMITH A O CORP COM 234
SMUCKER J M CO COM NEW 408
SNAP-ON INC COM 292
SOLARWINDS CORP COM 21
SONOCO PROD CO COM 190
SPECTRUM BRANDS HLDGS INC 108
SPIRIT AEROSYSTEMS HLDGS INC CL A 132
SPROUTS FMRS MKT INC COM 12
SS&C TECHNOLOGIES HLDGS INC COM 410
STANLEY BLACK & DECKER INC COM 871
STATE STR CORP COM 810
STEEL DYNAMICS INC COM 234

Field: Page; Sequence: 28; Value: 24

Field: Sequence; Type: Arabic; Name: PageNo 27 Field: /Sequence

Field: /Page

Abbott Laboratories Stock Retirement Plan
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued
December 31, 2020
(Dollars in thousands)
Identity of party involved/ Description of asset/ Rate/ Maturity
Common stock - continued
STERICYCLE INC COM 200
STERIS PLC ORD 481
STERLING BANCORP DEL COM 111
SVB FINANCIAL GROUP COMMON STOCK 629
SYNCHRONY FINL COM 639
SYNEOS HEALTH INC COM 147
SYNNEX CORP COM STK 109
SYNOPSYS INC COM 90
SYNOVUS FINL CORP COM 152
T ROWE PRICE GROUP INC 808
TAKE-TWO INTERACTIVE SOFTWARE INC COM STK 55
TANDEM DIABETES CARE INC COM 20
TAPESTRY INC COM 277
TARGA RES CORP COM 186
TCF FINL CORP NEW COM 175
TELADOC HEALTH INC 45
TELEDYNE TECH 184
TELEDYNE TECHNOLOGIES INC COM 453
TELEFLEX INC COM 228
TELEPHONE & DATA SYS INC COM STK 60
TEMPUR SEALY INTL INC 41
TERADATA CORP DEL COM STK 20
TERMINIX GLOBAL HLDGS INC COM 217
TEXTRON INC COM 346
TFS FINL CORP COM STK 27
THOR INDS INC COM STK 153
TIFFANY 502
TIMKEN CO COM 153
TOLL BROS INC COM 162
TORO CO COM 31
TRADEWEB MKTS INC CL A 26
TRANE TECHNOLOGIES PLC COM 1,098
TRANSDIGM GROUP INC COM 795
TRANSUNION COM 54
TRAVEL & LEISURE CO 121
TREEHOUSE FOODS INC COM 77
TRIMBLE INC COM TRIMBLE INC 531
TRINITY IND INC COM 77
TRIPADVISOR INC COM 93
TWILIO INC CL A 251
TWITTER INC COM 1,337
TYSON FOODS INC CL A COM (DELAWARE) 592
U.S. CELLULAR CORP COM 15
UBIQUITI INC COM 15
UGI CORP NEW COM 234
ULTA BEAUTY INC 34
UMPQUA HLDGS CORP COM 107
UNDER ARMOR INC CL A 105
UNDER ARMOUR INC CL C COM 94
UNITED AIRLINES HOLDINGS INC COM 399
UNITED RENTALS INC COM 533
UNITED THERAPEUTICS CORP DEL COM STK 212
UNITY SOFTWARE INC COM 20

Field: Page; Sequence: 29

Field: Sequence; Type: Arabic; Name: PageNo 28 Field: /Sequence

Field: /Page

Abbott Laboratories Stock Retirement Plan
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued
December 31, 2020
(Dollars in thousands)
Identity of party involved/ Description of asset/ Rate/ Maturity
Common stock - continued
UNIVAR SOLUTIONS INC 102
UNUM GROUP 145
UNVL HEALTH SERVICES INC CL B COM 321
US FOODS HLDG CORP COM 236
V F CORP COM 820
VAIL RESORTS INC COM 322
VALMONT INDS INC COM 118
VALVOLINE INC COM 138
VARIAN 437
VEREIT INC COM 262
VERISIGN INC COM 285
VIACOMCBS INC CL A 14
VIACOMCBS INC NPV CLASS B 646
VIASAT INC COM 62
VIATRIS INC 714
VIRGIN GALACTIC HLDGS INC COM 7
VIRTU FINL INC CL A 6
VISTRA CORP COM 301
VONTIER CORP COM 129
VOYA FINL INC COM 237
VROOM INC COM 7
VULCAN MATERIALS CO COM 618
WABTEC CORP COM 421
WATERS CORP COM 441
WATSCO INC COM 238
WAYFAIR INC CL A 42
WEBSTER FNCL CORP WATERBURY CONN COM 121
WEC ENERGY GROUP INC COM 925
WESTERN ALLIANCE BANCORPORATION COM 188
WESTERN UNION CO 233
WESTLAKE CHEM CORP COM STK 89
WESTN DIGITAL CORP COM 534
WESTROCK CO COM 351
WEX INC COM 264
WHIRLPOOL CORP COM 350
WHITE MOUNTAINS INSURANCE GROUP COM 98
WILEY JOHN & SONS INC CL A 63
WILLIAMS CO INC COM 771
WILLIAMS SONOMA INC COM 211
WILLIS TOWERS WATSON PLC COM 857
WINTRUST FINL CORP COM 112
WOODWARD INC COM 218
WYNDHAM HOTELS & RESORTS INC COM 175
WYNN RESORTS LTD COM 268
XCEL ENERGY INC COM 1,117
XEROX HLDGS CORP COM NEW 120
XPO LOGISTICS INC COM 323
XYLEM INC COM 581
YUM CHINA HLDGS INC COM 677
ZEBRA TECHNOLOGIES CORP CL A 56
ZILLOW GROUP INC COM 223
ZILLOW GROUP INC COM CLASS C 528
ZIMMER BIOMET HLDGS INC COM 1,010

Field: Page; Sequence: 30; Options: NewSection; Value: 29

Field: Sequence; Type: Arabic; Name: PageNo 29 Field: /Sequence

Field: /Page

Abbott Laboratories Stock Retirement Plan
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued
December 31, 2020
(Dollars in thousands)
Identity of party involved/ Description of asset/ Rate/ Maturity
Common stock - continued
ZIONS BANCORPORATION N A 222
ZYNGA INC 50
Total Common stock 4,819,600
Mutual funds
PIMCO ALL ASSET FUND 96,224
REITs
1ST INDL RLTY TR INC COM 171
AGNC INVT CORP COM 266
ALEXANDRIA REAL ESTATE EQUITIES INC COM 754
AMERICAN CAMPUS CMNTYS INC COM 188
AMERICAN HOMES 4 RENT COMMON STOCK 256
AMERICOLD RLTY TR COM 221
ANNALY CAP MGMT INC COM 376
APPLE HOSPITALITY REIT INC COM NEW 87
AVALONBAY CMNTYS REIT 713
BRANDYWINE RLTY TR SH BEN INT NEW REIT 65
BRIXMOR PPTY GROUP INC COM 158
BROOKFIELD PPTY REIT INC COM 3
BSTN PPTYS INC 470
CAMDEN PPTY TR SH BEN INT 298
CORESITE RLTY CORP COM CORESITE REALTY CORP 53
CORP OFFICE PPTYS TR COM 94
COUSINS PPTYS INC 159
CUBESMART 206
CYRUSONE INC COM 276
DOUGLAS EMMETT INC COM REIT 156
DUKE RLTY CORP COM NEW REIT 464
EMPIRE ST RLTY TR INC CL A 42
EPR PPTYS COM SH BEN INT 78
EQTY LIFESTYLE PPTYS INC REIT 205
EQTY RESDNTL 688
EQUITY COMMONWEALTH 102
ESSEX PPTY TR REIT 488
EXTRA SPACE STORAGE INC COM 140
FEDERAL RLTY INVT TR SH BEN INT NEW 206
GAMING & LEISURE PPTYS INC COM 292
HEALTHCARE TR AMER INC CL A NEW 192
HEALTHPEAK PROPERTIES INC 518
HIGHWOODS PPTYS INC COM 131
HOST HOTELS & RESORTS INC REIT 321
HUDSON PACIFIC PROPERTIES INC COM 116
INVITATION HOMES INC COM 531
IRON MTN INC NEW COM 113
JBG SMITH PROPERTIES COM 123
KILROY RLTY CORP COM 212
KIMCO RLTY CORP COM 199
LIFE STORAGE INC COM 182
MEDICAL PPTYS TR INC COM REIT 364
MID-AMER APT CMNTYS INC COM 458
NATIONAL RETAIL PPTYS INC COM STK 225
NEW RESIDENTIAL INVT CORP COM NEW 133

Field: Page; Sequence: 31; Value: 29

Field: Sequence; Type: Arabic; Name: PageNo 30 Field: /Sequence

Field: /Page

Abbott Laboratories Stock Retirement Plan
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued
December 31, 2020
(Dollars in thousands)
Identity of party involved/ Description of asset/ Rate/ Maturity
REITs - continued
OMEGA HEALTHCARE INVS INC REIT 256
OUTFRONT MEDIA INC COM 90
PARAMOUNT GROUP INC COM 55
PARK HOTELS & RESORTS INC COM 130
RAYONIER INC REIT 125
REALTY INCOME CORP COM 690
REGENCY CTRS CORP COM 247
REXFORD INDL RLTY INC COM 195
SIMON PROPERTY GROUP INC COM 190
SL GREEN RLTY CORP 140
SPIRIT REALTY CAPITAL INC COM 135
STARWOOD PROPERTY TRUST INC COM REIT 169
STORE CAPITAL CORPORATION 258
SUN COMMUNITIES INC COM 507
UDR INC COM STK 358
VENTAS INC REIT 578
VICI PPTYS INC COM 435
VORNADO RLTY TR COM 211
W P CAREY INC COM 386
WEINGARTEN RLTY INVS COM 84
WELLTOWER INC COM REIT 855
WEYERHAEUSER CO COM 792
Total REITs 18,379
Collective trust funds
BLACKROCK INTERNATIONAL MULTI CAP EQUITY FUND 100,355
CAPITAL GROUP EUROPACIFIC GROWTH TRUST 434,878
CAPITAL GROUP GROWTH FUND OF AMERICA TRUST 1,130,643
CAPITAL GROUP WASHINGTON MUTUAL INVESTORS TRUST 252,933
GW&K SMALL-MID CAP CORE EQUITY FUND 132,378
*NORTHERN TRUST COLLECTIVE WORLD ex-U.S. INDEX FUND 97,002
*NORTHERN TRUST COLLECTIVE ACWI ex-U.S. INDEX FUND 20,080
PIMCO TOTAL RETURN COLLECTIVE TRUST FUND 289,889
SSGA RUSSELL SMALL/MID CAP INDEX FUND CLASS K 826,333
SSGA S&P 500 INDEX FUND CLASS K 1,370,380
SSGA U.S. BOND INDEX FUND CLASS K 213,861
SSGA TARGET RETIREMENT 2020 238,653
SSGA TARGET RETIREMENT 2025 395,188
SSGA TARGET RETIREMENT 2030 408,694
SSGA TARGET RETIREMENT 2035 358,621
SSGA TARGET RETIREMENT 2040 290,642
SSGA TARGET RETIREMENT 2045 241,581
SSGA TARGET RETIREMENT 2050 165,560
SSGA TARGET RETIREMENT 2055 88,021
SSGA TARGET RETIREMENT 2060 36,926
SSGA TARGET RETIREMENT 2065 3,639
SSGA TARGET RETIREMENT INCOME 137,385
*NORTHERN TRUST COLLECTIVE SHORT TERM INVESTMENT FUND 6,759
Total Collective trust funds 7,240,401

Field: Page; Sequence: 32; Value: 29

Field: Sequence; Type: Arabic; Name: PageNo 31 Field: /Sequence

Field: /Page

Abbott Laboratories Stock Retirement Plan
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued
December 31, 2020
(Dollars in thousands)
Identity of party involved/ Description of asset/ Rate/ Maturity
Futures contracts
EQUITY FUTURES OFFSET - LONG (2,218)
FUT MAR 21 EMINI S&P 500 375
FUT MAR 21 IMMEMINI MDCP 1,843
Total Futures contracts -
Corporate debt
ABBVIE INC 2.15% DUE 11-19-2021 REG 2,642
AERCAP IRELAND CAP 4.5% DUE 05-15-2021 2,228
AIR LEASE CORP MED 2.25% DUE 01-15-2023 2,259
AIRCASTLE LTD 5.125% DUE 03-15-2021 2,621
AMERICAN ELEC PWR CO INC FLTG RT DUE 11-01-2023 REG 5,007
AMERN HONDA FIN FLTG RT 2.87288% DUE 06-27-2022 1,710
ASSURANT INC SR NT DUE 03-26-2021/03-26-2019 REG 206
AT&T INC FLTG RT 02-15-2023 1,214
ATHENE GLOBAL FUNDING 144A FRN 07-01-2022 3,677
AVIATION CAP GROUP 2.875% DUE 01-20-2022 210
AVIATION CAP GROUP FLTG RT 1.1405% DUE 06-01-2021 1,888
B A T CAP CORP 3.36738% 08-15-2022 6,546
BOC AVIATION PTE LTD GLOBAL MEDIUM TERM VAR RT DUE 05-02-2021 3,094
BOEING CO 1.875% DUE 06-15-2023 916
BOEING CO 4.508% DUE 05-01-2023 3,242
BRIXMOR OPER PARTNERSHIP LP FLTG 02-01-2022 999
BROADCOM INC 3.125% DUE 04-15-2021 REG 1,006
CALIFORNIA ST FLTG RT 04-01-2047 BEO TAXABLE 2,599
CHARTER COMMUNICATIONS OPER LLC FRNS 02-01-2024 1,025
CITIBANK N A FLTG RT 05-20-2022 REG 4,107
DAIMLER FIN NORTH AMER LLC CORP FLTG 144A 02-15-2022 2,015
DNB BK ASA MEDIUM VAR RT .80838% DUE 12-02-2022 504
DOMINION ENERGY GAS HLDGS LLC FORMERLY SR NT 2018 SER A FLTG DUE 06-15-2021 REG 501
DOMINION ENERGY INC FLTG RT DUE 09-15-2023 1,903
DUKE ENERGY CORP NEW SR NT FLTG 03-11-2022 1,307
DUKE ENERGY CORP NEW SR NT FLTG RATE 144A DUE 05-14-2021 BEO 2,404
ENBRIDGE INC FLTG 02-18-2022 5,003
EQUIFAX INC SR NT FLTG DUE 08-15-2021 REG 301
EXPORT-IMP BK INDI FRN SNR MTN 08/22 2,494
FIRST ABU DHABI BK FR SNR EMTN 04/22 1,006
GEN MLS INC-MEDIUM TERM NTS-BOOK TRANCHE# TR 00148 6.41% 10-15-2022 1,985
GEN MTRS FINL CO FIXED 4.2% DUE 11-06-2021 5,154
GENERAL MTRS CO FLTG RT 1.0825% DUE 09-10-2021 3,003
GOLDMAN SACHS FLTG RT .800857% DUE 12-09-2026 3,421
GOLDMAN SACHS FLTG RT 1.28575% DUE 04-26-2022 1,166
GULF STREAM MERIDIAN 2 LTD / GULF NT CL A-1 FLTG 144A 3C7 2.63463% 10-15-2029 2,000
HARLEY DAVIDSON FLTG RT 1.16763% DUE 03-02-2021 1,900
HEWLETT PACKARD FLTG RT .91425% DUE 10-05-2021 1,100
KOMMUNEKREDIT 2.5% SNR EMTN 14/04/22 USD 8,232
KRAFT HEINZ FOODS CO GTD SR NT FLTG DUE 08-10-2022 REG 1,696
LLOYDS BKG GROUP PLC NT FLTG RATE DUE 06-21-2021 REG 2,910
MFA 2020-NQM2 TR FLTG RT 1.381% DUE 04-25-2065 2,264
MITSUBISHI UFJ FINL GROUP INC SR NT FLTGDUE 07-26-2023 REG 2,052
MITSUBISHI UFJ FINL GROUP INC SR NT FLTGRATE DUE 07-25-2022 REG 3,078
MIZUHO FINL GROUP INC SR NT FLTG DUE 07-16-2023/07-16-2022 REG 3,720
MUFG UN BK N A SAN FLTG RT .720286% DUE 12-09-2022 1,071
NAVIENT PRIVATE ED LN TR 2020-I 1.10088% 04-15-2069 3,000

Field: Page; Sequence: 33; Value: 29

Field: Sequence; Type: Arabic; Name: PageNo 32 Field: /Sequence

Field: /Page

Abbott Laboratories Stock Retirement Plan
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued
December 31, 2020
(Dollars in thousands)
Identity of party involved/ Description of asset/ Rate/ Maturity
Corporate debt - continued
NEXTERA ENERGY CAPITAL HLDGS INC FLTG RT 02-25-2022 705
NISSAN MTR ACCEP CORP NT FLTG RATE 144A DUE 07-13-2022 BEO 992
NOMURA HLDGS INC 2.648% 01-16-2025 1,175
OCCIDENTAL PETE CORP FLTG 08-15-2022 1,372
PAC GAS & ELEC CO FIXED 1.75% DUE 06-16-2022 4,513
PAC GAS & ELEC CO FIXED 3.75% DUE 02-15-2024 213
PAC GAS & ELEC CO FLTG RT 1.52463% DUE 11-15-2021 2,501
PAC GAS & ELEC CO FLTG RT 1.6695% DUE 06-16-2022 1,801
PACIFIC GAS & ELEC CO 3.25% 06-15-2023 104
PACIFIC GAS & ELEC CO 3.4% 08-15-2024 320
PACIFIC GAS & ELECTRIC CO 3.85% 11-15-2023 106
PHILLIPS 66 FLTG RT .77588% DUE 02-15-2024 1,601
PVTPL AIA GROUP LTD FLTG 09-20-2021 1,299
PVTPL AREIT 2020-CRE4 LTD/AREIT SR SECD NT CL SER 20-CRE4 CL A STEP 04-14-2037 2,021
PVTPL AVIATION CAP GROUP 2.875% 01-20-2022 506
PVTPL BAMLL COML MTG SECS SR 2019-AHT CL A FLTG 03-15-2034 690
PVTPL CBAM 2018-8 LTD LLC NT CL A-1 FLTG 3C7 10-20-2029 BEO 3,974
PVTPL CENT CLO 19 LTD / CENT CLO 19 CORPSR SECD NT CL A-1A 144A 10-29-2025 473
PVTPL CMO GOSFORTH FUNDING 2012-1 PLC STEP UP DUE 08-25-2060 BEO 431
PVTPL CMO MF1 2019-FL2 LTD FLTG 12-25-2034 4,161
PVTPL CMO THE BANCORP COML MTG TR SER 2019-CRE6 TR CLS A FLTG DUE 09-15-2036 722
PVTPL CMO WELLS FARGO COML MTG TR SER 2017-HSDB CL A VAR RT 12-13-2023 1,467
PVTPL CMO WELLS FARGO COMMERCIAL MTG TST SR 2012-C10 CL AFL VAR RT 09-15-2022 2,594
PVTPL CMO WFRBS COML MTG SER-2014-C21 CL-ASBF FLTG 08-16-2047 BEO 483
PVTPL CROWN PT CLO 6 LTD/CROWN PT CLO 6 LLC SR SECD NT CL A-1 FLTG 144A VAR RT 2,811
PVTPL DAIMLER FIN NORTH AMER LLC NT FLTG RATE 02-22-2022 5,036
PVTPL IMPERIAL TOBBACCO FINANCE 3.75% 07-21-2022 4,275
PVTPL JACKSON NATL LIFE GLOBAL FDG SECD FLTG 06-11-2021 5,010
PVTPL JAMESTOWN CLO LTD SER 14-4A CL A1BR VAR 07-15-2026 116
PVTPL KEB HANA BK SR NT FLTG DUE 10-02-2022 BEO 802
PVTPL MF1 2020-FL3 LTD SR SECD NT CL A FLTG 07-15-2035 BEO 2,017
PVTPL MF1 MULTIFAMILY HOUSING MORTGAGE LO SR 20-FL4 CL A VAR RT DUE 11-15-2035 2,404
PVTPL NAVIENT PRIVATE ED REFI LN TR SRS 20-HA CL A 1.31% DUE 01-15-2069 3,334
PVTPL NELNET STUDENT LN TR FLTG RT SER 19-2A CL A 06-27-2067 BEO 2,742
PVTPL NISSAN MTR ACCEP CORP FLTG 09-21-2021 BEO 3,491
PVTPL PALMER SQUARE LN FDG 144A FLTG RT SER 19-3A CL A1 08-20-2027 BEO 3,390
PVTPL PALMER SQUARE LN FDG 2020-1 CL A1 FLTG RT DUE 02-20-2028 4,740
PVTPL PALMER SQUARE LN FDG SER 18-2A CL A1 FLTG 07-15-2026 1,452
PVTPL SMB PRIVATE ED LN TR 2020-PT-A SR 20-PTA CL A-1 VAR RT 09-15-2054 1,317
PVTPL SOCIAL PROFESSIONAL LOAN PROGRAM LL VAR RT DUE 10-25-2036 BEO 327
PVTPL THL CR WIND RIV SER 12-1A CL AR2 FLTG 01-15-2026 BEO 206
PVTPL TRALEE CDO LTD SER 18-5A CL A1 FLTG 10-20-2028 BEO 2,986
PVTPL VOLKSWAGEN GROUP AMER FIN LLC .75%DUE 11-23-2022 BEO 5,015
PVTPL Z CAP CR PARTNERS CLO SER 15-1A CL A1R FLTGT RT 07-16-2027 2,700
PVTPLTRALEE CLO III LTD SER 2014-3A CL A-R FLTG 10-20-2027 1,024
QNB FINANCE LTD FRN 31/05/21 1,505
ROYAL BK SCOTLAND FLTG RT 1.62588% DUE 05-15-2023 4,247
SANTANDER UK PLC NT FLTG DUE 06-01-2021 REG 1,949
SEMPRA ENERGY NT FLTG RATE DUE 03-15-2021 REG 1,601
SHELL INTL FIN B V DISC COML PAPER 4/2 YRS 1&2 01-19-2021 3,000
SOFI PROFESSIONAL LN PROGRAM 2020-C POSTGRADUATE LN AST BKD NT 1.95% 02-15-2046 3,305
SOUTHERN CALIF EDISON CO FLTG RT DUE 12-03-2021 REG 3,502
STANDARD CHARTERED PLC NT FLTG 144A DUE 09-10-2022/09-10-2021 BEO 2,008

Field: Page; Sequence: 34; Value: 29

Field: Sequence; Type: Arabic; Name: PageNo 33 Field: /Sequence

Field: /Page

Abbott Laboratories Stock Retirement Plan
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued
December 31, 2020
(Dollars in thousands)
Identity of party involved/ Description of asset/ Rate/ Maturity
Corporate debt - continued
STD CHARTERED PLC FLTG RT 1.26% DUE 10-14-2023 5,335
SUMITOMO MITSUI FINL GRP FLTG RT DUE 10-18-2022 BEO 4,440
SYNCHRONY BK 3% DUE 06-15-2022 1,033
UBS GROUP FDG SWITZ AG NT FLTG 144A DUE 08-15-2023/08-15-2022 BEO 5,049
WELLS FARGO & CO FLTG RT 1.28575% DUE 01-24-2023 1,210
WELLS FARGO & CO NEW NT FLTG DUE 10-31-2023/10-31-2022 REG 2,032
ZOETIS INC SR NT FLTG 08-20-2021 601
Total Corporate debt 242,622
Government debt
FEDERAL HOME LN MTG CORP POOL #ZM5146 4%12-01-2047 BEO 614
FEDERAL HOME LN MTG CORP POOL #ZM6064 4%04-01-2048 BEO 109
FEDERAL HOME LN MTG CORP POOL #ZM8299 4%09-01-2048 BEO 570
FEDERAL HOME LN MTG CORP POOL #ZT0712 4%10-01-2048 BEO 481
FHLMC 4% MBS 01/01/2050 USD'SD-8039 POOL #SD8039 4 01-01-2050 465
FHLMC POOL #SD8006 4.0% 08-01-2049 352
FHLMC SD8012 4.0% 09-01-2049 BEO 18
GNMA 2016-H17 MTG PASS THRU CTF CL MX FC08-20-2066 765
GNMA 2016-H20 REMIC PASSTHRU CTF CL MX-PT 09-20-2066 1,659
GNMA REMIC PASSTHRU SER 2016-H11 CLS F 05-20-2066 151
UNITED STATES TREASURY BILLS 01-28-2021 335
UNITED STATES TREASURY .375% DUE 03-31-2022 45,845
UNITED STATES TREASURY N/B 2% DUE 02-15-2050 REG 760
UNITED STATES TREASURY NOTES .125% DUE 06-30-2022 REG 65,510
UNITED STATES TREASURY NOTES 0.125% 11-30-2022 29,203
Total Government debt 146,837
Certificate of deposit
SUMITOMO MITSUI BKG CORP N Y BRH INSTL CDTD 02-06-2020 FRN 11-05-2021 4,509
Private 40-Act mutual funds
PIMCO Short-Term Floating NAV Portfolio II 357,819
PIMCO Short-Term Portfolio 52,115
Total Private 40-Act mutual funds 409,934
*Loans to participants, 3.00% to 9.25% 88,523
$ 13,067,029
*Represents a party-in-interest transaction.
(a) Cost information omitted as all investments are fully participant directed.

Field: Page; Sequence: 35; Value: 29

Field: Sequence; Type: Arabic; Name: PageNo 34 Field: /Sequence

Field: /Page

Field: Split-Segment; Name: 8

FINANCIAL STATEMENTS AND

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

ABBOTT LABORATORIES STOCK RETIREMENT PLAN (PUERTO RICO)

DECEMBER 31, 2020 and 2019

Field: Page; Sequence: 36

Field: /Page

C O N T E N T S

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 3
FINANCIAL STATEMENTS
STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS 5
STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS 6
NOTES TO FINANCIAL STATEMENTS 7
SUPPLEMENTAL SCHEDULE
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) 16

Field: Page; Sequence: 37

Field: /Page

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Plan Administrator and Plan Participants

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

Opinion on the financial statements

We have audited the accompanying statements of net assets available for benefits of Abbott Laboratories Stock Retirement Plan (Puerto Rico) (the “Plan”) as of December 31, 2020 and 2019, the related statement of changes in net assets available for benefits for the year ended December 31, 2020, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2020 and 2019, and the changes in net assets available for benefits for the year ended December 31, 2020 in conformity with accounting principles generally accepted in the United States of America.

Basis for opinion

These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plan is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Plan’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Field: Page; Sequence: 38; Options: NewSection; Value: 3

Field: Sequence; Type: Arabic; Name: PageNo 3 Field: /Sequence

Field: /Page

Supplemental information

The schedule of assets (held at end of year) as of December 31, 2020 (“supplemental information”) has been subjected to audit procedures performed in conjunction with the audit of the Plan’s financial statements. The supplemental information is the responsibility of the Plan’s management. Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental information. In forming our opinion on the supplemental information, we evaluated whether the supplemental information, including its form and content, is presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the financial statements as a whole.

/s/ Grant Thornton LLP

We have served as the Plan’s auditor since 2014.

Chicago, Illinois

June 28, 2021

Field: Page; Sequence: 39

Field: Sequence; Type: Arabic; Name: PageNo 4 Field: /Sequence

Field: /Page

Field: Split-Segment; Name: 9

Abbott Laboratories Stock Retirement Plan (Puerto Rico)
STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS
December 31, 2020 and 2019
(Dollars in thousands)

Field: Rule-Page

Field: /Rule-Page

2020 2019
Assets
Cash $ 4 $ 19
Investments, at fair value 201,807 168,599
Notes receivable from participants 4,410 4,458
Due from brokers 4 151
Accrued interest income 3 17
Total assets 206,228 173,244
Liabilities
Accrued investment expenses 3 3
Due to brokers 15 60
Total liabilities 18 63
NET ASSETS AVAILABLE FOR BENEFITS $ 206,210 $ 173,181

The accompanying notes are an integral part of these statements.

Field: Page; Sequence: 40; Options: NewSection; Value: 5

Field: Sequence; Type: Arabic; Name: PageNo 5 Field: /Sequence

Field: /Page

Abbott Laboratories Stock Retirement Plan (Puerto Rico)
STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS
Year ended December 31, 2020
(Dollars in thousands)

Field: Rule-Page

Field: /Rule-Page

Additions
Contributions
Employer $ 2,013
Participant 4,233
Rollovers 274
Total contributions 6,520
Investment income
Net appreciation in fair value of investments 35,269
Interest and dividends 2,302
Net investment income 37,571
Interest income on notes receivable from participants 198
Total additions 44,289
Deductions
Benefits paid to participants 11,225
Other expenses 35
Total deductions 11,260
NET INCREASE 33,029
Net assets available for benefits
Beginning of year 173,181
End of year $ 206,210

The accompanying notes are an integral part of this statement.

Field: Page; Sequence: 41; Value: 5

Field: Sequence; Type: Arabic; Name: PageNo 6 Field: /Sequence

Field: /Page

Field: Split-Segment; Name: 10

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

NOTES TO FINANCIAL STATEMENTS

December 31, 2020 and 2019

NOTE A - DESCRIPTION OF THE PLAN

The following description of the Abbott Laboratories Stock Retirement Plan (Puerto Rico) (the “Plan”) provides only general information. Participants should refer to the Plan document for a more complete description of the Plan’s provisions.

General

The Plan was established January 1, 2013 in conjunction with Abbott Laboratories (“Abbott”) separating into two publicly traded companies – Abbott and AbbVie Inc. (“AbbVie”). The Plan covers employees of Abbott’s selected subsidiaries and affiliates in Puerto Rico (the “Company”). The employees of the Company had previously participated in the former Abbott Laboratories Stock Retirement Plan (Puerto Rico), which, effective January 1, 2013 was renamed AbbVie Puerto Rico Savings Plan (the “Former Plan”) and sponsorship was assumed by an affiliate of AbbVie.

The Plan is a profit-sharing plan containing a cash or deferred arrangement intended to qualify for favorable tax treatment under sections 1081.01 (a) and (d) of the Puerto Rico Internal Revenue Code of 2011, as amended. In addition, the Plan provides an arrangement by which employees may invest in Abbott shares. Employees of the Company may, after meeting certain employment requirements, voluntarily participate in the Plan. Beginning March 2017, newly hired employees in certain specified Abbott divisions and business units became eligible to participate in the Plan under a different structure (“Abbott Green” employees).

The Plan’s sponsor is Abbott Healthcare (Puerto Rico) Ltd. Alight Solutions serves as the record keeper of the Plan. The Northern Trust Company (“Custodian”) and Banco Popular de Puerto Rico (“Trustee”) serve as the Plan’s custodian and trustee, respectively. The Plan is subject to the Employee Retirement Income Security Act of 1974, as amended (“ERISA”).

Contributions and Vesting

Contributions to the Plan are paid to a trust administered by the Trustee. An investment committee (the “Committee”) may direct the Trustee to establish investment options of the Committee’s choosing.

Employees are eligible to commence participation in the Plan on any entry date following their date of hire. Eligible employees electing to participate may contribute from 2% (or 1%, for Abbott Green participants) to 25% of their eligible earnings, subject to certain limitations. Participants may choose to make their contributions from either pretax earnings or after-tax earnings, or both. Participants who have attained age 50 before the end of the Plan year and who are making the maximum pretax contribution are eligible to make catch-up contributions. Participants may elect to invest their contributions in any or all of the investment options, except for investment options closed to new contributions.

Field: Page; Sequence: 42; Options: NewSection; Value: 7

Field: Sequence; Type: Arabic; Name: PageNo 7 Field: /Sequence

Field: /Page

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2020 and 2019

NOTE A - DESCRIPTION OF THE PLAN - Continued

Contributions and Vesting - Continued

Employer matching contributions to the Plan are made each payroll period based on the participating employees’ eligible earnings. Excluding the Abbott Green participants, the employer contribution for the year ended December 31, 2020 was 5% of the participant’s eligible earnings if the participant elected to contribute at least 2% of eligible earnings to the Plan. Effective with the first pay period ending after March 1, 2017, employer matching contributions for Abbott Green participants are made at the rate of 100% up to a 3% deferral of eligible earnings. Employer contributions are invested each pay period according to the participant’s investment elections.

In connection with the January 1, 2013 separation of Abbott into two publicly traded companies, Abbott shareholders received as a tax-free distribution one share of AbbVie stock for every share of Abbott held as of the close of business on December 12, 2012, the record date for the distribution. Plan participants may continue to hold the AbbVie stock they received from the distribution that transferred from the Former Plan into their Plan accounts; however, they may not make new contributions or transfer existing contributions or earnings to purchase AbbVie stock in the Plan. AbbVie dividends are invested in the Plan’s default investment option.

Participants may direct the Trustee to sell all or a portion of the Abbott and AbbVie common shares held in their accounts and reinvest the proceeds in any of the other investment options available to the participants.

Participants are at all times fully vested in their own contributions and earnings thereon. Vesting in employer contributions and earnings thereon is based on the following vesting schedule:

Vesting
Service percentage
Less than two years 0 %
Two years or more 100 %

Abbott Green participants are also fully vested in matching contributions upon death or qualifying disability.

Non-vested portions of employer contributions and earnings thereon are forfeited as of an employee’s termination date. Forfeitures are used to (1) restore any forfeitures of participants who returned to service with the Company within a given period of time, (2) pay Plan expenses and (3) reduce future employer contributions if terminated participants do not return to service within the given period of time. In 2020, approximately $39,100 of forfeitures were used to reduce employer contributions. Forfeitures totaling approximately $117,900 and $117,000 were available at the end of 2020 and 2019, respectively.

Field: Page; Sequence: 43; Value: 7

Field: Sequence; Type: Arabic; Name: PageNo 8 Field: /Sequence

Field: /Page

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2020 and 2019

NOTE A - DESCRIPTION OF THE PLAN - Continued

Distributions and In-Service Withdrawals

Following retirement, termination or death, participants or their beneficiaries may elect to receive a distribution in installments, a single lump sum or a partial lump sum. Participants may elect a direct rollover of their accounts. Distribution must be made by the 1 st of April following the year the participant reaches age 72 (or age 70 ½, if reached prior to January 1, 2020 ) or, if earlier, the 31 st of December following the year in which the participant dies. Interest, dividends and other earnings will continue to accrue on such deferred amounts.

Prior to termination, participants are permitted to withdraw their after-tax contributions (after-tax contributions made on or after January 8, 2016 may be withdrawn from the Plan only after being held for two or more years) and rollover contributions (including merged-in plan rollover accounts) and, after age 59 ½, may also withdraw pretax contributions. Distributions are made in cash or, to the extent contained in the participant’s account, a participant may elect distribution of Abbott and AbbVie common shares, and in each case, are subject to certain limitations.

Notes Receivable from Participants

Participants may convert their vested account balances into one or two loans to themselves. The borrowing may not exceed the lesser of the current market value of the assets allocated to their vested accounts or 50% of all of their Plan accounts up to $50,000, subject to Puerto Rico Internal Revenue Code limitations and restrictions. Participants pay interest on such borrowings at the prime rate in effect at the time the participant loan is made. Loans must be repaid within five years (or by the employee’s anticipated retirement date, if sooner) unless the loan is used for the purchase of the primary residence of the employee, in which case the repayment period can be extended to a period of fifteen years (or until the employee’s anticipated retirement date, if sooner). Repayment is generally made through periodic payroll deductions or by sending in a payment, but a loan may be repaid in a lump sum at any time. Post-termination loan repayments are permitted. For employees whose account is distributed during the repayment period, the balance of the outstanding loan is netted from their Plan distribution.

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Accounting

The financial statements have been prepared using the accrual basis of accounting.

Field: Page; Sequence: 44; Value: 7

Field: Sequence; Type: Arabic; Name: PageNo 9 Field: /Sequence

Field: /Page

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2020 and 2019

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and changes therein, and disclosure of contingent assets and liabilities. Actual results may differ from those estimates.

Investment Valuation

The Plan uses the following methods and significant assumptions to estimate the fair value of investments:

Common stock and mutual funds - Valued at the published market price per share or unit multiplied by the number of shares or units held.

Collective trust funds - Valued at the net asset value (“NAV”) provided by the administrator of the fund. The NAV is used as a practical expedient to estimate fair value. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. Participants are permitted to make redemptions from the funds on a daily basis. Certain funds require five days’ notice for a Plan level redemption.

The following tables summarize the basis used to measure investments at fair value at December 31, 2020 and 2019 (dollars in thousands):

2020 Basis of Fair Value Measurement — Quoted Prices in Active Markets Significant Other Observable Inputs Significant Unobservable Inputs Measured at NAV Total
Common stock $ 92,499 $ - $ - $ - $ 92,499
Mutual funds 13,336 - - - 13,336
Collective trust funds - - - 95,972 95,972
Total investments at fair value $ 105,835 $ - $ - $ 95,972 $ 201,807

Field: Page; Sequence: 45; Value: 7

Field: Sequence; Type: Arabic; Name: PageNo 10 Field: /Sequence

Field: /Page

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2020 and 2019

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Investment Valuation - Continued

| | Basis
of Fair Value Measurement | | | | |
| --- | --- | --- | --- | --- | --- |
| | Quoted | Significant | | | |
| | Prices in | Other | Significant | | |
| | Active | Observable | Unobservable | Measured at | |
| 2019 | Markets | Inputs | Inputs | NAV | Total |
| Common stock | $ 78,489 | $ - | $ - | $ - | $ 78,489 |
| Mutual funds | 13,728 | - | - | - | 13,728 |
| Collective trust funds | - | - | - | 76,382 | 76,382 |
| Total investments at fair value | $ 92,217 | $ - | $ - | $ 76,382 | $ 168,599 |

Notes Receivable from Participants

Notes receivable from participants are measured at their unpaid balance plus any accrued but unpaid interest. Delinquent loans are reclassified as distributions based upon the terms of the Plan. No allowance for credit losses has been recorded as of December 31, 2020 or 2019.

Income Recognition

Purchases and sales of securities are recorded on a trade-date basis. Interest income is recorded on the accrual basis. Dividends are recorded on the ex-dividend date. Net realized and unrealized appreciation/depreciation is recorded in the accompanying statement of changes in net assets available for benefits as net appreciation in fair value of investments.

Administrative Expenses

Participants are charged transaction fees for loan processing and commissions on purchases and sales of Abbott shares and sales of AbbVie shares. Investment fees for mutual funds and collective trusts are charged against the net assets of the respective fund. The Company pays other record-keeping and administration fees, where applicable.

Payment of Benefits

Benefits are recorded when paid.

Field: Page; Sequence: 46; Value: 7

Field: Sequence; Type: Arabic; Name: PageNo 11 Field: /Sequence

Field: /Page

Field: Split-Segment; Name: 11

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2020 and 2019

Field: Rule-Page

Field: /Rule-Page

NOTE C - INVESTMENTS

Distributions of Abbott common shares and conversions of participants’ common share account balances to participant loans or other investment options are recorded at fair market value.

A summary of Abbott common share data as of December 31, 2020 and 2019 is presented below:

2020 2019
Abbott common shares, 605,942 and 631,512 shares, respectively (dollars in thousands) $ 66,345 $ 54,853
Market value per share $ 109.49 $ 86.86

NOTE D - RELATED-PARTY AND PARTY-IN-INTEREST TRANSACTIONS

The Plan holds units of collective trust funds managed by the Trustee. A significant portion of the Plan’s assets is invested in Abbott common shares. These transactions qualify as party-in-interest transactions; however, they are exempt from the prohibited transaction rules under ERISA. During 2020, the Plan received $900,000 in common stock dividends from Abbott.

Participants pay fees to the recordkeeper for loan transaction processing and for commissions on purchases and sales of Abbott shares and sales of AbbVie stock. These transactions qualify as permitted party-in-interest transactions.

NOTE E - PLAN TERMINATION

The Plan may be terminated at any time by Abbott upon written notice to the Trustee and Committee. All participants’ account balances would become fully vested upon Plan termination. Upon termination of the Plan, distributions of each participant’s share in the trust, as determined by the terms of the Plan, would be made to each participant. At the present time, Abbott has no intention of terminating the Plan.

Field: Page; Sequence: 47; Options: NewSection; Value: 12

Field: Sequence; Type: Arabic; Name: PageNo 12 Field: /Sequence

Field: /Page

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2020 and 2019

Field: Rule-Page

Field: /Rule-Page

NOTE F - TAX STATUS

The Plan received letters dated April 19, 2016 and December 2, 2019 from the Department of the Treasury of the Commonwealth of Puerto Rico that the Plan, as written, qualifies under Section 1081.01(a) of the Puerto Rico Internal Revenue Code of 2011, as amended and, consequently, its enabling trust is exempt from local income tax. The Plan has been amended since receiving the letters. The Plan administrator believes that the Plan is designed and is currently being operated, in all material respects, in accordance with the applicable Puerto Rico Internal Revenue Code.

Accounting principles generally accepted in the United States of America require Plan management to evaluate tax positions taken by the Plan and recognize a tax liability if the organization has taken an uncertain position that more likely than not would not be sustained upon examination by the applicable taxing authorities. The Plan administrator has analyzed the tax positions taken by the Plan, and has concluded that as of December 31, 2020 and 2019, there are no uncertain positions taken or expected to be taken that would require recognition of a liability or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits in progress.

NOTE G - RISKS AND UNCERTAINTIES

In general, the investments provided by the Plan are exposed to various risks, such as interest rate, credit and overall market volatility risks. Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect participant accounts and the amounts reported in the statements of net assets available for benefits.

In March 2020, the World Health Organization declared COVID-19 a pandemic and recommended containment and mitigation measures worldwide. The pandemic is ongoing and has caused significant volatility and uncertainty in U.S. and international financial markets. The volatility in the markets has not resulted in a material change in the fair value of the Plan’s investments since December 31, 2020; however, the ultimate impact of COVID-19 on the Company, the Plan, and global financial markets will depend on future developments that are difficult to assess or predict, and the potential impact to the Plan’s net assets available for benefits and changes in net assets available for benefits is uncertain.

Field: Page; Sequence: 48; Value: 12

Field: Sequence; Type: Arabic; Name: PageNo 13 Field: /Sequence

Field: /Page

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2020 and 2019

Field: Rule-Page

Field: /Rule-Page

NOTE H - SUBSQUENT EVENTS

Management of the Plan has evaluated subsequent events from December 31, 2020 through the date these financial statements were issued. Management of the Plan is not aware of any subsequent events that require recognition or additional disclosure in these financial statements.

Field: Page; Sequence: 49; Value: 12

Field: Sequence; Type: Arabic; Name: PageNo 14 Field: /Sequence

Field: /Page

SUPPLEMENTAL SCHEDULE

Field: Page; Sequence: 50; Options: NewSection; Value: 15

Field: /Page

Field: Split-Segment; Name: 12

Abbott Laboratories Stock Retirement Plan (Puerto Rico)
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)
December 31, 2020
(Dollars in thousands)

Field: Rule-Page

Field: /Rule-Page

Identity of party involved/ — description of asset Cost (a) value
Common stock - employer securities
*Abbott Laboratories, common shares $ 66,345
Common stock
AbbVie Inc., common stock 26,154
Total Common stock 92,499
Mutual funds
PIMCO All Asset Fund 2,119
PIMCO Short Asset Investment Fund 8,347
Vanguard Mid-Cap Value Index Fund Admiral 2,870
Total Mutual funds 13,336
Collective trust funds
Blackrock International Opportunities Fund 2,106
Capital Group EuroPacific Growth Trust 6,396
Capital Group The Growth Fund of America Trust 17,002
Capital Group Washington Mutual Investors Trust 2,926
GW&K Small-Mid Cap Core Equity Fund 3,707
*Northern Trust Collective World ex-U.S. Index Fund 594
*Northern Trust Collective ACWI ex-U.S. Index Fund 93
PIMCO Total Return Collective Trust Fund 3,178
SSGA Russell Small/Mid Cap Index Fund 3,866
SSGA S&P 500 Index Fund 13,859
SSGA U.S. Bond Index Fund 1,524
SSGA Target Retirement 2020 5,077
SSGA Target Retirement 2025 7,735
SSGA Target Retirement 2030 6,610
SSGA Target Retirement 2035 5,266
SSGA Target Retirement 2040 4,894
SSGA Target Retirement 2045 3,414
SSGA Target Retirement 2050 2,181
SSGA Target Retirement 2055 1,104
SSGA Target Retirement 2060 240
SSGA Target Retirement 2065 42
SSGA Target Retirement Income 4,095
*Northern Trust Collective Short Term Investment Fund 63
Total Collective trust funds 95,972
*Loans to participants, 3.25% to 5.50% 4,410
$ 206,217
*Represents a party-in-interest transaction.
(a) Cost information omitted as all investments are fully participant directed.

Field: Page; Sequence: 51; Options: NewSection; Value: 16

Field: Sequence; Type: Arabic; Name: PageNo 16 Field: /Sequence

Field: /Page

Field: Split-Segment; Name: 13

EXHIBIT INDEX

| Exhibit
No. | Exhibit |
| --- | --- |
| 23.1 | Consent of Independent Registered Public Accounting Firm – Abbott Laboratories Stock Retirement Plan. |
| 23.2 | Consent of Independent Registered Public Accounting Firm – Abbott Laboratories Stock Retirement Plan (Puerto Rico). |

Field: Page; Sequence: 52

Field: /Page

SIGNATURE

The Plan . Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the employee benefit plan) have duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.

ABBOTT LABORATORIES STOCK RETIREMENT PROGRAM

Date: June 28, 2021
Sean J. Treacy
Plan Administrator

Field: Page; Sequence: 53; Options: Last

Field: /Page